Medical Conferences

Continuing Medcial Education 2011

Hereditary Hemorrhagic Telangiectasia (HHT):
Diagnosis, Treatment and Management
Saturday, November 5, 2011
Dallas, Texas

The conference was held at the University of Texas - Southwestern Medical Center, T. Boone Pickens Biomedical Building. Thank you to the speakers who volunteered their time to provide a comprehensive overview of HHT including diagnostic, management and treatment protocols based on the most current research and clinical guidelines.

The University of Texas Southwestern Medical Center designates this educational activity for a maximum of 7.5 AMA PRA Category 1 Credit(s). All participants in the CME program will receive their certificate within the next few weeks.

We would like to acknowledge O'Brien Pharmacy, Silver Sponsor of the CME Program, for their financial support of this educational activity.

HHT CME Brochure
 

CDC Conference: HHT in the 21st Century

The Hereditary Hemorrhagic Telangiectasia (HHT) Foundation International, in conjunction with the Center for Disease Control and Prevention (CDC), held a landmark conference on March 5 – 6, 2008 at the Tom Harkin Global Communications Center in Atlanta, Georgia.

The purpose of this conference was to define and prioritize objectives to improve clinical outcomes, enhance the quality of life for those affected by HHT, and reduce intrinsic and extrinsic costs related to HHT treatment.

Please click on the following links to learn more about the Conference:
HHT/CDC Executive Summary
HHT/CDC Conference Program
HHT/CDC Goals and Objectives
Dr. Chestnutt’s Presentation
Dr. Peter Terrys Presentation
Dr. Reed Pyeritz Presentation

Over 60 health care professionals including: emergency medicine physicians, school nurses, family practitioners/internal medicine, pediatric specialists, physician assistants, dentists and dental hygienists, dermatologists, gastroenterologists, otolaryngologists, hematologists, pulmonologists, neurologists, cardiologists, radiologists, geneticists as well as representatives from governmental and non-governmental organizations attended this national conference. You can view participants by clicking on Participant List.

HHT is a long neglected national health problem that affects 75,000 Americans. HHT is a multisystem vascular genetic disorder producing arterioveneous malformations in the brain and lung which may result in stroke or hemorrhage. Twenty percent of children and adults with HHT die prematurely or may become disabled due to lack of recognition by the medical community. These outcomes are largely preventable with proper intervention. Timely diagnosis and treatment of HHT could improve outcomes and quality of life for people living with HHT while eliminating $6.6 billion in avoidable health care costs.

The conference was the first step in addressing this national health issue by identifying outreach programs that will increase surveillance, increase early recognition of people affected with this genetic condition, and support life saving interventions

For more information, contact Marianne Clancy, Executive Director of the HHT Foundation International, at 800-448-6389 or email her at mariannes.clancy@hht.org .

NIH Workshop

Hereditary Hemorrhagic Telangiectasia Vascular Biology and Pathophysiology
HHT Foundation in conjunction with the National Institute of Health (NIH) sponsored an HHT Workshop for basic scientific research in Bethesda, Maryland on June 8 and 9, 2006. The conference provided an opportunity for NIH to formulate an HHT research plan. The workshop included a mix of keynote talks, platform presentations, and open discussion on several themes, including:

1. Transforming Growth Factor-Beta Pathway and HHT
2. Endothelial Biology and HHT
3. Vascular Biology and HHT
4. Chemical Genomics and HHT
5. Organ Pathophysiology in HHT
6. Click on the link below to view the Overview of the Program:

http://www.genome.gov/19519386